OC Reduced Heavy, Prolonged Menstrual Bleeding in Study

Major Finding: Complete resolution of abnormal menstrual symptoms was achieved in 44% of those receiving an oral contraceptive containing estradiol valerate/dienogest vs. 4% of those given placebo.

Data Source: A multinational, double-blind phase III trial of 135 women.

Disclosures: The study was funded by Bayer Schering Pharma AG, which is developing E2V/DNG. Dr. Jensen has received research support from Bayer and Warner-Chilcott, and served as consultant for Bayer and Schering Plough. His coauthors disclosed employment with Bayer Schering and consultant roles with Bayer.